Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: antiviral monoclonal antibodies - Lanier Biotherapeutics/Centers for Disease Control and Prevention

Next Previous
Search
Drug Profile

Research programme: antiviral monoclonal antibodies - Lanier Biotherapeutics/Centers for Disease Control and Prevention

Latest Information Update: 07 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abeome Corporation; Centers for Disease Control and Prevention
  • Developer Centers for Disease Control and Prevention; Lanier Biotherapeutics
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Zika virus infection

Most Recent Events

  • 05 Oct 2021 Biophtha has merged with Abeome Corporation to form Lanier Biotherapeutics
  • 28 May 2021 No recent reports of development identified for research development in Zika-virus-infection in USA (Parenteral)
  • 19 Apr 2017 Abeome Corporation and Centers for Disease Control and Prevention agree to co-develop monoclonal antibody therapeutic in USA for Zika virus infection

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top